Login to Your Account

Promethera eyes Canadian cell therapy filing post Cytonet deal

By Cormac Sheridan
Staff Writer

Tuesday, April 19, 2016

DUBLIN – Promethera Biosciences SA is acquiring the principal assets and expertise of Cytonet GmbH & Co KG in a stock-based deal that will combine two organizations focused on developing cell therapies for diseases of the liver.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription